ArrakisTx

This entrepreneurial chemist is blazing new paths in biotech

As a small biotech company with new technology at the frontier of the known drug discovery universe, it may feel like you're charting a course alone in a dark, cold, and empty void with hailing frequencies open, but with no incoming transmissions. But you

Prior to 2015, I had a casual relationship, at best, with targeting RNA. The bulk of my nearly three decades of experience up to that point was with drugging protein targets using a variety of modalities, but principally small molecules. This typically me

We are moving rapidly toward escape velocity in our RNA expedition at Arrakis. We want to mark this progress with some updates and perspectives in the Dark Matter blog. In the months ahead, we are rolling out a series of posts called "Fearlessly Forward"

The post Video: Fearlessly Forward appeared first on Arrakis Therapeutics.

A handful of startups have formed in recent years with plans to target RNA with small molecules. Many have caught the attention of big drugmakers.

September 6, 2022 BioPharma Dive Drugging RNA with pills: small molecules for a big frontier

STAT health tech correspondent Katie Palmer joins us this episode to recap the J.P. Morgan Healthcare Conference.

January 13, 2022 STAT The Readout Loud Podcast

January 11, 2022 Fierce Biotech Amgen teams up with Arrakis to destroy disease-causing RNA in 75M research deal